Form 4: BridgeBio Pharma Director Acquires Stock Options
SEC Form 4
Jennifer E. Cook, a director of BridgeBio Pharma, acquired stock options for 26,014 shares of common stock on June 21, 2024.
Summary
- On June 21, 2024, Jennifer E. Cook, a director at BridgeBio Pharma, acquired stock options for 26,014 shares.
- The exercise price of the stock options is $27.36.
- One-third of the shares underlying the stock option will vest each year after June 21, 2024, with full vesting on June 21, 2027, contingent upon continued service on the board.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a routine disclosure of stock option grants to a director, which is neither particularly positive nor negative.
Positives
- The acquisition of stock options by a director signals confidence in the company's future performance.
Industry Context
Form 4 filings are standard practice and provide transparency into insider transactions, allowing investors to track the actions of company directors and officers.
Stakeholder Impact
- Shareholders can monitor insider transactions to gauge management's confidence in the company.
Key Dates
| Date | Description |
|---|---|
| 06/21/2024 | Date of the stock option acquisition. |
| 06/21/2024 | Vesting start date for the stock options. |
| 06/20/2034 | Expiration date of the stock options. |
| 06/21/2027 | Date of full vesting for the stock options. |
| 06/25/2024 | Date of the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.